Seshadri Neervannan, Chief Operating Officer of Tarsus Pharmaceuticals, Inc., filed a Form 4 on September 9, 2026, reporting the sale of 4,564 shares of common stock on September 4, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 4,564 shares of common stock disposed of on September 4, 2026, at a price of $85 per share.
  • Trading plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2025.
  • Direct beneficial ownership after transaction: 78,532 shares held directly following the reported transaction.
  • ESPP shares included: The post-transaction direct holding includes 305 shares acquired under the issuer's Employee Stock Purchase Plan on June 30, 2026.
  • Indirect holding: 475 shares held indirectly by the reporting person's daughter, who shares his household; he disclaims beneficial ownership of those shares.

Neervannan Seshadri's Planned Share Sale and Remaining Ownership at Tarsus Pharmaceuticals

According to the filing, Seshadri Neervannan, identified as Chief Operating Officer of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), disposed of 4,564 shares of common stock on September 4, 2026, at a price of $85 per share. The filing notes that "the sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025." The form was signed by Jeffrey Farrow as Attorney-in-Fact on September 9, 2026.

Following the transaction, the filing reports that Neervannan directly holds 78,532 shares. The filing discloses that this total includes 305 shares acquired under the issuer's Employee Stock Purchase Plan on June 30, 2026. In addition, 475 shares are reported as held indirectly, related to the reporting person's daughter who shares his household. The filing states that the reporting person "disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes."

No derivative securities transactions were reported in Table II of the filing. The Form 4 was filed as an individual, one-reporting-person filing, and the box indicating the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) was checked.

What Was Disclosed

The filing reports a single open-market sale of 4,564 common shares at $85 by Tarsus Pharmaceuticals' COO on September 4, 2026, executed under a 10b5-1 plan, leaving the officer with 78,532 directly held shares.